Somnomed Limited · ASX:SOM
Somnomed — Shareholder Meeting (November 2024)
11 slides from Somnomed's shareholder meeting presentation, Nov 27, 2024
Slide 1: Investor Presentation Annual General Meeting
Investor Presentation Annual General Meeting 27th November 2024 Treatment focused. Technology driven.
Slide 2: Disclaimer
Disclaimer This document has been prepared as a summary only and does not contain all information about the Company’s assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s securities. This document should be read in co
Slide 3: Trading and Company Update
Trading and Company Update
Slide 4: Building the foundations for profitable growth
Building the foundations for profitable growth 3-year priorities FY25 Jan 2024 – Jun 2024 Sustainable growth Execution and and innovation delivery Reset • Return to double digit revenue growth ✓ People and culture: build a high performing team and culture of • 10%+ EBITDA1 margins efficiency and imp
Slide 5: Core Business strengthens in Q1 FY25
Core Business strengthens in Q1 FY25 +16% Revenue growth $100m Revenue growth of +18.2% YoY (+20.3% CC) +6% Earnings growth Additional revenue and disciplined cost management Revenue (AUD m)1 generating Q1 FY25 EBITDA2 > FY23 and FY24 respective EBITDA2 Capacity uplift >30% increase in manufacturing
Slide 6: New top tier leadership team
New top tier leadership team Jonathan Vowels: VP Manufacturing and Operations • Former Operations Director SEA British American Tobacco • Over 25 years manufacturing and supply chain experience Ye-Fei Guo: Chief Financial Officer • Former VP Finance at Brookfield, trained at PwC • CA, over 20 years
Slide 7: FY25 Revised Guidance
FY25 Revised Guidance
Slide 8: FY25 original guidance and guidance upgrade
FY25 original guidance Revenue EBITDA1 Capex c. $100m >$5m $3-4m FY25 guidance upgrade Revenue EBITDA1 Capex c. $105m >$7m $3-4m vs. $91.7m FY24 vs. $0.6m FY24 1 EBITDA excludes AASB16 leases, share/option expenses, unrealised foreign exchange gain/loss, one off restructuring costs and discontinued
Slide 9: Rest Assure
Rest Assure ®
Slide 10: Rest Assure status Oct-24 and next steps
Rest Assure® status Oct-24: • FDA cleared Rest Assure® as the first oral device with built-in compliance monitoring • Clearance includes the oral device and software platform incl. patient app, physician platform, docking station and cloud systems Rest Assure® next steps: • New FDA 510k submission u
Slide 11: For further information please contact
For further information please contact: Investor Relations: IR@somnomed.com.au © November 2024 SomnoMed 11